STAT+

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more

Health Jonathan Wosen

STAT Plus: A bespoke genetic therapy is helping Susannah. Can similar drugs be made at scale for other rare diseases?

Pharmalot Ed Silverman

STAT Plus: Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B

Pharmalot Ed Silverman

STAT Plus: A U.K. trade group scolds Novo again — this time for remarks made by its CEO

Health tech Lizzy Lawrence

STAT Plus: AI app claiming to diagnose STIs from penis pictures shut down after FTC scrutiny

Health tech Mario Aguilar

STAT Plus: Big Health gets FDA nod for its digital therapy for insomnia

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: A strong start for Madrigal’s MASH drug launch

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Purdue overdose-reversal device, a discontinued Merck trial, and more

Biotech Allison DeAngelis

STAT Plus: AI drug developers Recursion, Exscientia to merge

Biotech Elaine Chen

STAT Plus: Eli Lilly boosts 2024 revenue guidance by $3 billion on Mounjaro, Zepbound sales

Business Tara Bannow

STAT Plus: Orlando Health, a $6 billion Florida powerhouse, is expanding into Alabama

Biotech Andrew Joseph

STAT Plus: Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England

Health tech Lizzy Lawrence

STAT Plus: Medicare finalizes reimbursement rule for breakthrough medical devices

Insurance Bob Herman

STAT Plus: CVS removes top Aetna leader as higher medical costs eat further into profits

In the Lab Megan Molteni

STAT Plus: The race to build better CRISPR delivery vehicles is heating up

Pharmalot Ed Silverman

STAT Plus: FDA scolds Bristol Myers over a misleading website for a cancer treatment

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Roche plans for Flatiron, underwhelming Novo Nordisk earnings, and more

Biotech Elaine Chen and Andrew Joseph

STAT Plus: Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data

A STAT Investigation Casey Ross, Lizzy Lawrence, Bob Herman, and Tara Bannow

STAT Plus: Health Care's Colossus: How UnitedHealth turned a questionable artery-screening program into a gold mine

Pharma Andrew Joseph

STAT Plus: Supply issues weigh on Novo Nordisk as drugmaker stumbles with quarterly report

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a canceled Roche trial, low VC biotech funding, and more

Biotech Allison DeAngelis

STAT Plus: Biotech mogul Arie Belldegrun extends empire with launch of $600 million credit firm

Exclusive Elizabeth Cohen

STAT Plus: ‘Jerking families around’: Canceled Roche rare disease trial devastates parents, angers researchers

Exclusive Allison DeAngelis

STAT Plus: Biotech VCs are pacing for another record-low year of fundraising amid glimpses of recovery

Health tech Lizzy Lawrence

STAT Plus: Jeff Shuren stabilized the FDA’s medical devices center, winning over industry but not all patients

Politics Isabella Cueto

STAT Plus: Lawmakers cast doubt on expert panel studying alcohol for 2025 dietary guidelines

Biotech Adam Feuerstein

STAT Plus: BioMarin to restrict hemophilia therapy to three countries, seeking to overcome slow sales

Pharmalot Ed Silverman

STAT Plus: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs